Publications en collaboration avec des chercheurs de Universidad de Sevilla (24)

2023

  1. Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer

    Cancers, Vol. 15, Núm. 5

  2. Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

2021

  1. Identification of predictive biomarkers of response to hsp90 inhibitors in lung adenocarcinoma

    International Journal of Molecular Sciences, Vol. 22, Núm. 5, pp. 1-18

2018

  1. Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160)

    Journal of Clinical Oncology

  2. Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer

    Oncotarget, Vol. 9, Núm. 28, pp. 19945-19960

  3. Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer

    Oncotarget, Vol. 9, Núm. 4, pp. 4395-4410

  4. MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

    Journal of Experimental and Clinical Cancer Research, Vol. 37, Núm. 1

  5. The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction

    Scientific Reports, Vol. 8, Núm. 1

  6. Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis

    Thrombosis Research, Vol. 167, pp. 50-56

2017

  1. Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer

    Oncotarget, Vol. 8, Núm. 62, pp. 105196-105210

  2. Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement

    Clinical Lung Cancer, Vol. 18, Núm. 6, pp. 667-674.e1

  3. Results from the Phase III Randomized Trial of Onartuzumab plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung

    Journal of Clinical Oncology, Vol. 35, Núm. 4

2016

  1. Clinicopathologic features of advanced squamous NSCLC

    Journal of Thoracic Oncology, Vol. 11, Núm. 9, pp. 1411-1422

2015

  1. Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer

    PLoS ONE, Vol. 10, Núm. 3

  2. Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer

    Oncotarget, Vol. 6, Núm. 8, pp. 6151-6159

  3. Immunologic checkpoint blockade in lung cancer

    Seminars in Oncology, Vol. 42, Núm. 3, pp. 402-417

  4. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 7, pp. 763-774

2014

  1. MicroRNA clusters: Dysregulation in lung adenocarcinoma and COPD

    European Respiratory Journal, Vol. 43, Núm. 6, pp. 1740-1749

  2. MicroRNA-dependent regulation of transcription in non-small cell lung cancer

    PLoS ONE, Vol. 9, Núm. 3

2013

  1. Identification of proteomic signatures associated with lung cancer and COPD

    Journal of Proteomics, Vol. 89, pp. 227-237